Financial statements Farmacja Polska Apteki Główne
Balance sheet data of FARMACJA POLSKA APTEKI GŁÓWNE
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|---|---|---|---|---|---|
Total assets | 34 287 750,62 | 37 827 526,87 | 39 010 638,24 | 39 768 247,77 | 29 301 917,50 | 33 230 557,55 |
A. Fixed assets | 17 720 913,71 | 22 263 469,72 | 22 724 891,96 | 21 916 621,23 | 9 181 432,93 | 9 263 245,50 |
B. Current assets | 16 566 836,91 | 15 564 057,15 | 16 285 746,28 | 17 851 626,54 | 20 120 484,57 | 23 967 312,05 |
C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Total liabilities | 34 287 750,62 | 37 827 526,87 | 39 010 638,24 | 39 768 247,77 | 29 301 917,50 | 33 230 557,55 |
A. Equity | 11 021 853,00 | 11 323 442,04 | 11 129 035,98 | 11 851 055,34 | 726 860,99 | 2 238 798,17 |
B. Liabilities and provisions for liabilities | 23 265 897,62 | 26 504 084,83 | 27 881 602,26 | 27 917 192,43 | 28 575 056,51 | 30 991 759,38 |
I. Long-term liabilities | 1 276 001,42 | 1 224 025,71 | 1 026 438,59 | 818 852,19 | 575 229,97 | 1 084 714,44 |
II. Short-term liabilities | 21 649 948,20 | 24 935 633,12 | 26 645 288,67 | 26 817 324,24 | 27 710 514,54 | 29 593 744,94 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.